CrystecPharma to help develop inhaled formulation for respiratory conditions

SignalRx's SF2523 is a novel, small molecule dual PI3K-BRD4 inhibitor with a synergistic action on two pathways associated with the development of lung cancer and idiopathic pulmonary fibrosis

picture of

Breaking News

BD glass syringes capable of storage at deep cold temperatures

An analysis of approximately 2000 syringes showed no negative impact on key product functions when stored at -20°C and ...

Almac and Queen’s University Belfast collaboration passes midpoint

The KTP project has achieved multiple successful outcomes including dissemination through peer-reviewed publication and ...

Boehringer Ingelheim and OBT advance oncology candidate

The Boehringer Ingelheim drug candidate was discovered in a partnership with Oxford BioTherapeutics and enabled by ...

Delivering fixed-dose combination therapies with hard capsules: part I

In this article, authors Dr Jnanadeva Bhat and Ms Anita Solanki describe how fixed-dose combination therapies can be ...

Hookipa announces clinical collaboration with Merck USA

The collaboration will evaluate the combination of Hookipa’s arenaviral immunotherapeutic, and Merck’s Keytruda as ...

CytoSMART reopens research grant applications for Autumn

Through the grant, applicants can apply for either a Lux2, Lux3 FL, or an Omni live-cell imaging microscope, which they ...

Manufacturing vaccines, digital twins and lessons learned: part I

Using a digital replica of the manufacturing process, the pharmaceutical industry is exploring the ability of virtual ...

CPI launches RNA Centre of Excellence

To prepare for global demand for the technology, CPI is expanding capacity at its site in Darlington to include GMP ...

PharmaLex to join interdisciplinary vaccine initiative

The PharmaLex team will contribute to develop and qualify mathematical and statistical models that will be made ...

Developing optimised formulations with minimal drug substance

Advances in in silico and experimental techniques mean that APIs and prototype formulations can be thoroughly ...

Using ddPCR to accurately quantify AAV viral titre and integrity

Gene therapy is primed to become the next major development in medicine and bring relief to patients living with ...

Convenient magnesium supplementation: putting patients and consumers first

Martin Koeberle and Verena Garsuch of HERMES PHARMA explore how the application of specific formulation expertise and ...

Aptamer and Bio-Works collaborate on gene therapy scale up project

Under the agreement, Aptamer will develop an Optimer ligand capable of binding and eluting of a viral vector

Yposkesi joins BioPhorum CGT consortium

Key challenges facing biopharmaceutical manufacturers include ensuring production efficiency while operating in a ...

Featured Companies

Reports